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In this issue of Chemistry & Biology, Schust et al. [1]
report the discovery of a small molecule (Stattic) that
inhibits the binding of a high affinity phosphopeptide
for the SH2 domain of Stat3. Stattic is a new tool for
studying Stat3 signaling and demonstrates that the
SH2 domain is not a dead target.
Signal transducer and activator of transcription 3 (Stat3)
has received a lot of attention in the past decade
because its constitutive activation leads to aberrant
growth and survival of human tumors [2]. Stat3 trans-
duces signals from IL-6 family cytokines, epidermal
growth factor, platelet-derived growth factor, and
others. When the cytokine or growth factor binds to its
receptor on the cell surface, the receptors become
phosphorylated on tyrosine residues and Stat3 is re-
cruited through its SH2 domain. Tyr705 of Stat3 then
becomes phosphorylated by JAK kinases, Src-family
kinases, or the kinase activity of the receptor. On disso-
ciating from the receptor, two Stat3 molecules dimerize
via reciprocal pTyr705-SH2 domain interactions and the
dimer translocates to the nucleus where it initiates the
transcription of various genes. Relevant to cancer are
the Bcl-2-family of antiapoptotic proteins, cyclin D1,
c-myc, and others related to survival and cell cycling.
Stat3 is a recognized target for anticancer drug develop-
ment [3], and to inhibit its activity one could potentially
target the SH2 domain, the DNA binding domain, or
the transactivation domain. Targeting the SH2 domain
would prevent recruitment to growth factor or cytokine
receptors, impede dimer formation, and block transcrip-
tional activity.
SH2 domains, found in a variety of proteins, are
approximately 100-residue cassettes that recognize
phosphotyrosine residues and enable recruitment of
proteins to cell surface receptors or focal adhesions to
form signaling complexes [4]. Amino acids that deter-
mine the binding specificity for individual SH2 domains
are located 2-5 positions C-terminal to the pTyr [5].
Phosphopeptide complexes with the SH2 domains of
important targets such as Src, Lck, and Grb2 were easily
studied by NMR and X-ray crystallography, which led to
very successful structure-based peptidomimetic inhibi-
tor development programs in industry and academia [6].
The consensus sequence for Stat3 SH2 domain rec-
ognition was found to be pYXXQ [7, 8], which was con-
firmed by a combinatorial phosphopeptide library [9]
and a survey of Stat3 docking sites [10]. Unfortunately,
NMR or crystal structures of pYXXQ peptide bound to
Stat3 have not been published to date, so SH2 domain
inhibitor development has been done with targeted
libraries based on phosphopeptides [10–14]. One struc-
ture-affinity study resulted in a high affinity modifiedpeptide (2) which showed an IC50 of 125 nM in a fluores-
cence polarization assay [14] (Figure 1).
The pharmaceutical industry has largely abandoned
the SH2 domain as a target because of its requirement
of a negatively charged phosphotyrosine or pTyr mimic,
which is difficult to deliver to intracellular targets. To
date, no high throughput screens targeting SH2 do-
mains have appeared in the literature.
Schust et al. [1] have stepped in and screened over
17,000 small molecules for their ability to compete with
a high-affinity phosphopeptide targeted to the SH2
domain of Stat3. Interestingly, 144 compounds inhibited
phosphopeptide-protein interactions by >60%, the
activity cut-off in their screen. Secondary screens of
inhibition of IL-6 driven Stat3 nuclear localization and
inhibition of phopsho-Stat3-DNA binding identified 6-
nitrobenzo[b]thiophene-1,1-dioxide as a top candidate
(1, Figure 1). This compound, named Stattic (Stat3 three
inhibitory compound), is selective for Stat3 over Stat1,
Stat5, and Lck. Stattic appears to be susceptible to
Michael addition because it is only inhibitory in the
absence of dithiothreitol in a fluorescence polarization
assay. Inhibition increases with time and temperature
which suggests alkylation of Stat3. Cys687, on the op-
posite side of the protein from the phosphopeptide
binding face, may be the modified residue. If so, Stattic
may not be a direct competitor of phosphopeptide bind-
ing, but it may instead alter the conformation of the SH2
domain. The corresponding residue in Stat1 and Stat5 is
tyrosine, and Cys687 does not appear to have a corre-
sponding amino acid in Lck, which might account for
selective inhibition of Stat3. Unfortunately, attempts to
localize the interaction using mass spectrometry have
not been conclusive to date. We await the successful
completion of these experiments.
Other approaches to inhibitor discovery for SH2
domains have been tried. Virtual screening exercises
have resulted in compounds with much lower affinity
than phosphopeptides for Lck [15] and Src [16]. Song
et al. [17] performed a virtual screen against the SH2
domain of Stat3 and discovered STA-21 (3, Figure 1).
Although this compound inhibited Stat3 activity in cells
as well as binding of activated protein to DNA, no evi-
dence was offered that it actually inhibited phosphopep-
tide binding to the protein. Could STA-21 bind to the
DNA binding domain?
A distinction should be made between a Stat3 inhibi-
tor and a Stat3 pathway inhibitor. The former inhibits
the protein by direct binding, as in the case of Stattic
and the phosphopeptides, whereas the latter refers to
compounds that result in reduced activation of Stat3
by indirect means. In recent years, several compounds
have been reported to reduce Stat3 phosphorylation
and/or expression, but they do not bind to Stat3. For ex-
ample, in a screening program to discover Stat3 inhibi-
tors, Blaskovitch et al. [18] discovered that cucurbitacin
(4), a steroidal natural product, reduces Stat3 phosphory-
lation, but does not directly bind to Stat3. The analog
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ered in the Search for Stat3 Inhibitorscucurbitacin Q (5) is also a potent Stat3 pathway inhibi-
tor [19]. Given the interest in this pathway, other small
molecules will undoubtedly continue to appear in the
literature.
This discovery of a small molecule that can inhibit
phosphopeptide binding to an SH2 domain is a great ac-
complishment which shows that these domains are still
potential targets for drug delivery. In a broader sense,
Stattic is an example of a small molecule inhibitor of pro-
tein-protein interactions, which are very important for
signal transduction in the cell. The big advantage that
Stattic holds over phosphopeptides and their deriva-
tives is its ready transportation across cell membranes.
When interpreting the effects on cells, however, caution
must be exercised. Stattic with its Michael acceptor po-
tential may be subject to redox reactions and several
biochemical reactions in the cell that may affect path-
ways other than Stat3.
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